OmniAb Q2 Revenue Surges 244% to $13.4M, Raises Full-Year Outlook on Partner Momentum
OABI sits 77% above its 52-week low of $1.3.
Summary
OmniAb reported Q2 2026 revenue of $13.4 million, up 244% year-over-year, and raised full-year revenue and cash guidance. Partner programs advanced significantly, with two entering Phase 3 trials, reinforcing the platform's value.
Key Events · Earnings and Guidance · OABI
-
Revenue Triples on Milestone Surge
Q2 2026 revenue reached $13.4 million, up from $3.9 million in Q2 2025, driven primarily by milestone payments from partner programs advancing in the clinic.
-
Net Loss Narrows Significantly
Net loss improved to $5.9 million ($0.05/share) from $15.9 million ($0.15/share) a year ago, reflecting higher revenue and disciplined cost management.
-
Full-Year Guidance Raised
Management increased 2026 revenue guidance to $32–$36 million (from $28–$33 million) and year-end cash outlook to $37–$41 million (from $33–$38 million), signaling confidence in continued momentum.
-
Partner Pipeline Strengthens
Two partner programs (JNJ-5322 and M9140) advanced to Phase 3, TEV-'408 is moving to Phase 2b, and IMVT-1402 showed positive Phase 2 data. The company now has 34 programs in clinical or commercial stages.
Analysis · OABI · Industrial Applications And Services
A standout quarter saw revenue more than triple year-over-year to $13.4 million, fueled by milestone payments from advancing partner programs. The net loss narrowed sharply to $5.9 million from $15.9 million, and both full-year revenue and year-end cash guidance were raised. With $52 million in cash and a growing pipeline of 34 clinical-stage programs—including two newly entering Phase 3—the results validate the platform's ability to generate high-margin milestone revenue. The raised cash outlook extends the runway and reduces near-term dilution risk, though the company remains unprofitable on a GAAP basis.
At the time of this filing, OABI was trading at $2.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $324.7M. The 52-week trading range was $1.30 to $2.79. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.